Latest Breaking News On - Rebecca levinedirector - Page 1 : vimarsana.com

G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023

G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rebecca levinedirectorTherapeutics incCorporate communicationsResearch triangle parkRobertsvice presidentinvestor relationsPublic relations

G1 Therapeutics (GTHX) Reports Top Line Results from Phase 3 Trial of Trilaciclib

G1 Therapeutics (GTHX) Reports Top Line Results from Phase 3 Trial of Trilaciclib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rebecca levinedirectorExchange commissionTherapeutics incCorporate communicationsResearch triangle parkData monitoring committeeInvestor relations corporate communicationsWall streetConference callPrivate securities litigation reform actRobertsvice presidentInvestor relationsPublic relations

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesRebecca levinedirectorRaj malikExchange commissionTherapeutics incCorporate communicationsResearch triangle parkInvestor relations corporate communicationsPivotal phaseColorectal cancer expectedLabel expansionClinical trialsData readoutsEvaluate trilaciclib on target effectsEnhanced immune function

G1 Therapeutics (GTHX) Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin

G1 Therapeutics (GTHX) Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rebecca levinedirectorJared weissUniversity of north carolina chapel hillExchange commissionLineberger comprehensive cancer centerTherapeutics incCorporate communicationsResearch triangle parkDivision of oncologyInvestor relations corporate communicationsNorth carolina chapel hillSmall cell lung cancerinUnited statesLooking statementsthisPrivate securities litigation reform actRobertsvice president

G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRebecca levinedirectorRaj malikDrug administrationExchange commissionTherapeutics incCorporate communicationsResearch triangle parkInvestor relations corporate communicationsAmerican cancer societyFast trackTrack designationAccelerated approvalPriority reviewRolling reviewNew drug application